News Finding: This result was driven by a reduction in the risk of recurrent venous thromboembolism, with the risk of bleeding increasing to a minimal extent.
Paper Finding: This result was driven by a reduction in the risk of recurrent venous thromboembolism, the risk of bleeding increasing to a minimal extent.
News Context: During the 18-month treatment period, the primary outcome (the composite of recurrent venous thromboembolism or major bleeding at 18 months after randomization) occurred in 6 of 184 patients (3 percent) in the warfarin group and in 25 of 187 patients (13.5 percent) in the placebo group, resulting in a relative risk reduction of 78 percent in favor of warfarin. This result was driven by a reduction in the risk of recurrent venous thromboembolism, with the risk of bleeding increasing to a minimal extent. This benefit of anticoagulation was lost after anticoagulation was discontinued.
Paper Context: e One patient presented major bleeding 314 days after warfarin was initiated for recurrent venous thromboembolism. This result was driven by a reduction in the risk of recurrent venous thromboembolism, the risk of bleeding increasing to a minimal extent. However, this benefit of anticoagulation was lost after anticoagulation was discontinued.